Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in advanced biliary tract carcinoma
NCT03427242Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Nov 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in biliary tract carcinoma (BTC), sponsored by Fudan University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT03427242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427242.